XML 32 R13.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Inventories, Net | 12 Months Ended
--- | ---
Dec. 31, 2023
Inventory Disclosure [Abstract] |
Inventories, Net | Inventories, Net The Company's net inventories consisted of the following as of December 31:
|  | 2023 |  | 2022
Raw materials |  | $ | 12,619,092 |  |  | $ | 12,899,659 |
Consigned inventory |  | 149,701 |  |  | 168,923 |
Finished goods, net of reserve |  | 4,645,098 |  |  | 4,322,167 |
Total inventories |  | 17,413,891 |  |  | 17,390,748 |
less non-current inventories |  | (12,804,529) |  |  | (7,527,167) |
Total inventories classified as current |  | $ | 4,609,362 |  |  | $ | 9,863,581 |
The Company's non-current inventories consisted of the following as of December 31:
|  | 2023 |  | 2022
Vibativ - raw materials |  | $ | 6,611,426 |  |  | $ | 7,138,936 |
Vibativ - finished goods |  | 810,454 |  |  | — |
Kristalose - raw materials |  | 3,263,515 |  |  | — |
Vaprisol - raw materials |  | 1,170,641 |  |  | — |
Caldolor - finished goods |  | 67,307 |  |  | — |
Sancuso - raw materials |  | 574,502 |  |  | — |
Study drug - raw materials |  | 203,383 |  |  | 256,474 |
Study drug - finished goods |  | — |  |  | 131,757 |
Other products |  | 103,300 |  |  | — |
Total non-current inventory |  | $ | 12,804,529 |  |  | $ | 7,527,167 |
The Company purchases the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory of that raw material. API for the Company's Vaprisol and Vibativ brands were included in the assets associated with the acquisition of those brands and are also included in the raw materials inventory. As part of the Vibativ acquisition, the Company acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition. Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment. At December 31, 2023, there were no cumulative obsolescence or discontinuance losses necessary to recognize. At December 31, 2022, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.5 million.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration